Abstract
The aim of this study was to identify and evaluate novel prognostic markers for gastric cancer. Differential mRNA displays comparing paired tumor/normal stomach samples were assessed. Several differentially expressed cDNA fragments of candidate genes were identified, and one of these was further studied using quantitative reverse transcription-PCR in 140 human gastric carcinomas. To evaluate protein expression, immunohistochemical staining was performed in selected cases. One of the genes abundantly expressed in tumor tissue on the differential mRNA displays was identified as histone deacetylase 1 (HDAC). HDAC was overexpressed in the tumor tissue in 77% of the cases as determined by quantitative reverse transcription-PCR. Immunohistochemical staining revealed analogous results, showing strong expression in cancer cells. Patients were then classified into high (n=78) and low (n=62) expression groups according to the mean value of HDAC expression. High frequencies of lymph vessel and vascular vessel permeations, and advanced stage of the disease were recognized in the high expression group compared to the low expression group (p<0.05). Prognosis was significantly worse for the high expression group than for the low expression group (p<0.05), and multivariate analysis demonstrated that HDAC expression was an independent prognostic factor. Although not significantly different, lymph node metastasis was recognized more frequently in the high expression group (p=0.07). In conclusion, the findings show that HDAC expression is associated with aggressive behavior of primary gastric cancer, and imply that determination of the HDAC expression status is useful for predicting prognosis in patients with gastric cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 777-782 |
| Number of pages | 6 |
| Journal | Oncology reports |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Oct 1 2011 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Histone deacetylase 1 expression in gastric cancer. / Sudo, Tomoya; Mimori, Koshi; Nishida, Naohiro; Kogo, Ryunosuke; Iwaya, Takeshi; Tanaka, Fumiaki; Shibata, Kohei; Fujita, Hiromasa; Shirouzu, Kazuo; Mori, Masaki.
In: Oncology reports, Vol. 26, No. 4, 01.10.2011, p. 777-782.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Histone deacetylase 1 expression in gastric cancer
AU - Sudo, Tomoya
AU - Mimori, Koshi
AU - Nishida, Naohiro
AU - Kogo, Ryunosuke
AU - Iwaya, Takeshi
AU - Tanaka, Fumiaki
AU - Shibata, Kohei
AU - Fujita, Hiromasa
AU - Shirouzu, Kazuo
AU - Mori, Masaki
PY - 2011/10/1
Y1 - 2011/10/1
N2 - The aim of this study was to identify and evaluate novel prognostic markers for gastric cancer. Differential mRNA displays comparing paired tumor/normal stomach samples were assessed. Several differentially expressed cDNA fragments of candidate genes were identified, and one of these was further studied using quantitative reverse transcription-PCR in 140 human gastric carcinomas. To evaluate protein expression, immunohistochemical staining was performed in selected cases. One of the genes abundantly expressed in tumor tissue on the differential mRNA displays was identified as histone deacetylase 1 (HDAC). HDAC was overexpressed in the tumor tissue in 77% of the cases as determined by quantitative reverse transcription-PCR. Immunohistochemical staining revealed analogous results, showing strong expression in cancer cells. Patients were then classified into high (n=78) and low (n=62) expression groups according to the mean value of HDAC expression. High frequencies of lymph vessel and vascular vessel permeations, and advanced stage of the disease were recognized in the high expression group compared to the low expression group (p<0.05). Prognosis was significantly worse for the high expression group than for the low expression group (p<0.05), and multivariate analysis demonstrated that HDAC expression was an independent prognostic factor. Although not significantly different, lymph node metastasis was recognized more frequently in the high expression group (p=0.07). In conclusion, the findings show that HDAC expression is associated with aggressive behavior of primary gastric cancer, and imply that determination of the HDAC expression status is useful for predicting prognosis in patients with gastric cancer.
AB - The aim of this study was to identify and evaluate novel prognostic markers for gastric cancer. Differential mRNA displays comparing paired tumor/normal stomach samples were assessed. Several differentially expressed cDNA fragments of candidate genes were identified, and one of these was further studied using quantitative reverse transcription-PCR in 140 human gastric carcinomas. To evaluate protein expression, immunohistochemical staining was performed in selected cases. One of the genes abundantly expressed in tumor tissue on the differential mRNA displays was identified as histone deacetylase 1 (HDAC). HDAC was overexpressed in the tumor tissue in 77% of the cases as determined by quantitative reverse transcription-PCR. Immunohistochemical staining revealed analogous results, showing strong expression in cancer cells. Patients were then classified into high (n=78) and low (n=62) expression groups according to the mean value of HDAC expression. High frequencies of lymph vessel and vascular vessel permeations, and advanced stage of the disease were recognized in the high expression group compared to the low expression group (p<0.05). Prognosis was significantly worse for the high expression group than for the low expression group (p<0.05), and multivariate analysis demonstrated that HDAC expression was an independent prognostic factor. Although not significantly different, lymph node metastasis was recognized more frequently in the high expression group (p=0.07). In conclusion, the findings show that HDAC expression is associated with aggressive behavior of primary gastric cancer, and imply that determination of the HDAC expression status is useful for predicting prognosis in patients with gastric cancer.
UR - http://www.scopus.com/inward/record.url?scp=79960790220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960790220&partnerID=8YFLogxK
U2 - 10.3892/or.2011.1361
DO - 10.3892/or.2011.1361
M3 - Article
C2 - 21725604
AN - SCOPUS:79960790220
VL - 26
SP - 777
EP - 782
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 4
ER -